MX2023013972A - Compuesto de quinolinamina, metodo de preparacion y aplicacion del mismo en productos farmaceuticos. - Google Patents

Compuesto de quinolinamina, metodo de preparacion y aplicacion del mismo en productos farmaceuticos.

Info

Publication number
MX2023013972A
MX2023013972A MX2023013972A MX2023013972A MX2023013972A MX 2023013972 A MX2023013972 A MX 2023013972A MX 2023013972 A MX2023013972 A MX 2023013972A MX 2023013972 A MX2023013972 A MX 2023013972A MX 2023013972 A MX2023013972 A MX 2023013972A
Authority
MX
Mexico
Prior art keywords
compound
preparation
quinolinamine
method therefor
pharmaceuticals
Prior art date
Application number
MX2023013972A
Other languages
English (en)
Spanish (es)
Inventor
Feng He
Weikang Tao
Fanglong Yang
Minqiang Jia
Huanyu Tang
Yonglei Que
Original Assignee
Jiangsu Hengrui Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceuticals Co Ltd filed Critical Jiangsu Hengrui Pharmaceuticals Co Ltd
Publication of MX2023013972A publication Critical patent/MX2023013972A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2023013972A 2021-05-27 2022-05-27 Compuesto de quinolinamina, metodo de preparacion y aplicacion del mismo en productos farmaceuticos. MX2023013972A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110606803 2021-05-27
CN202110976020 2021-08-24
PCT/CN2022/095441 WO2022247920A1 (zh) 2021-05-27 2022-05-27 喹啉胺类化合物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
MX2023013972A true MX2023013972A (es) 2023-12-11

Family

ID=84228425

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013972A MX2023013972A (es) 2021-05-27 2022-05-27 Compuesto de quinolinamina, metodo de preparacion y aplicacion del mismo en productos farmaceuticos.

Country Status (11)

Country Link
US (1) US20240327388A1 (cg-RX-API-DMAC7.html)
EP (1) EP4349831B1 (cg-RX-API-DMAC7.html)
JP (1) JP7881616B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240014059A (cg-RX-API-DMAC7.html)
CN (1) CN117222639B (cg-RX-API-DMAC7.html)
AU (1) AU2022283404A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024741A2 (cg-RX-API-DMAC7.html)
CA (1) CA3219657A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023013972A (cg-RX-API-DMAC7.html)
TW (1) TW202313592A (cg-RX-API-DMAC7.html)
WO (1) WO2022247920A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202436295A (zh) * 2022-11-25 2024-09-16 大陸商江蘇恒瑞醫藥股份有限公司 喹啉胺類化合物的可藥用鹽、晶型及其製備方法
TW202436296A (zh) * 2022-11-25 2024-09-16 大陸商江蘇恒瑞醫藥股份有限公司 喹啉胺類化合物晶型及其製備方法
CN116854634B (zh) * 2023-06-27 2025-12-09 广东药科大学 一种选择性ces2抑制剂、其制备方法及其作为药物的用途
IL326865A (en) * 2023-08-30 2026-04-01 Jiangsu Chia Tai Fenghai Pharmaceutical Co Ltd Compound for regulating activity of microrna-124
WO2025201294A1 (zh) * 2024-03-26 2025-10-02 深圳信立泰药业股份有限公司 一种吲哚类化合物及其制备方法与miR上调应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5648599A (en) * 1998-09-11 2000-04-03 Kyorin Pharmaceutical Co. Ltd. Phosphonic ester derivatives and process for producing the same
CN102625804B (zh) 2009-06-12 2015-04-08 Abivax公司 用于治疗aids的化合物
JP2011026251A (ja) * 2009-07-27 2011-02-10 Kowa Co 2−アリールアミノキノリン化合物及びこれを有効成分として含有するエリスロポエチン産生促進剤
WO2012037351A1 (en) 2010-09-17 2012-03-22 Glaxosmithkline Llc Compounds
CN104109165A (zh) 2013-04-19 2014-10-22 四川海思科制药有限公司 4,5-二氢-吡唑并[3,4-c]吡啶-2-酮衍生物、其制备方法以及应用
CA2916623C (en) 2013-07-05 2021-09-14 Abivax Bicyclic compounds useful for treating diseases caused by retroviruses
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
EP3059236A1 (en) * 2015-02-23 2016-08-24 Abivax A new quinoline derivative for use in the treatment and prevention of viral infections
WO2017158201A1 (en) 2016-03-18 2017-09-21 Ratiopharm Gmbh Process for preparing quinolin-2-yl-phenylamine derivatives and their salts
EP3669873A1 (en) * 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
CA3168533A1 (en) * 2020-01-24 2021-07-29 The Trustees Of Princeton University Heterocyclic compounds and uses thereof

Also Published As

Publication number Publication date
JP7881616B2 (ja) 2026-06-29
KR20240014059A (ko) 2024-01-31
JP2024519993A (ja) 2024-05-21
WO2022247920A9 (zh) 2023-01-05
EP4349831A4 (en) 2024-09-04
CN117222639B (zh) 2026-07-10
TW202313592A (zh) 2023-04-01
BR112023024741A2 (pt) 2024-02-15
CN117222639A (zh) 2023-12-12
EP4349831A1 (en) 2024-04-10
WO2022247920A1 (zh) 2022-12-01
US20240327388A1 (en) 2024-10-03
AU2022283404A1 (en) 2023-11-30
EP4349831B1 (en) 2026-08-19
CA3219657A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
WO2022247920A9 (zh) 喹啉胺类化合物、其制备方法及其在医药上的应用
MX2022015531A (es) Derivado de piridina-pirimidina, metodo de preparacion y uso farmaceutico del mismo.
MX2022008881A (es) Compuesto heterociclico de pirimidin-4(3h)-ona, metodo de preparacion del mismo y su uso farmaceutico.
ZA202109010B (en) Compounds and methods for the treatment of covid-19
BR112022010254A2 (pt) Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio
GEP20257823B (en) Amino quinazoline derivatives as p2x3 inhibitors
CR20200157A (es) Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso
MX2023013890A (es) Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos.
MX2022015554A (es) Moduladores de molecula peque?a de interleucina 17 (il-17).
MX2024011705A (es) Compuesto heterociclico que contiene nitrogeno, metodo de preparacion y aplicacion farmaceutica
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
MX2023003576A (es) Compuesto como inhibidor de la akt cinasa.
PH12020551117A1 (en) Compositions for preventing or treating uveitis
PH12021551232A1 (en) Haloallylamine compounds and application thereof
MX2026001837A (es) Compuestos que contienen ciclobutilo
PH12021552004A1 (en) Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof
MX2025009098A (es) Sal y forma cristalina de un compuesto cicloalquenico y metodo de preparacion de estos y uso de estos
MX2025009374A (es) Compuesto que contiene trifluorometilsulfonilo
MX2025004676A (es) Derivado de piperidinopirimidina, metodo de preparacion del mismo y uso del mismo en medicina
MX2024015882A (es) Derivados de 3-(sulfonil o sulfonimidoil)prop-2-en-1-il]-2-oxo-1,2-dihidropiridina-3-carboxamida
MX2025006915A (es) Preparación farmacéutica de un compuesto de imidazolinona, método de preparación y uso de esta
MX2023007150A (es) Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos.
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
PH12022552553A1 (en) Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity